News

circle_logo2

CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy

LA JOLLA, Calif., May 7, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy

Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients  LA JOLLA, Calif., April 30, 2020 – CalciMedica Inc. …

FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND

Regions Hospital in St. Paul, Minnesota has begun a Phase 2 clinical study of CM4620-IE in patients with severe COVID-19 pneumonia this week, and Henry …

CalciMedica to Present Results of PD/PK Study in Acute Pancreatitis Patients for Its CRAC Channel Inhibitor CM4620 at APA Annual Meeting

LA JOLLA, CA, November 7, 2019 /PRNewswire/ — Kenneth Stauderman, Ph.D., CalciMedica’s Chief Scientific Officer, is presenting a poster at the American Pancreas Association annual …

Henry Ford Hospital Physician Presents Results from the Initial Patient Study of CalciMedica’s CRAC Channel Inhibitor CM4620 in Acute Pancreatitis at ACEP Meeting

LA JOLLA, CA, October 30, 2019 /PRNewswire/ — Joseph Miller, MD, MS, a physician at the Henry Ford Health System in Detroit, MI, and a …

Scroll to Top